Meeting
2023 ASCO Genitourinary Cancers Symposium
Long-term safety and tolerability of darolutamide and duration of treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the ARAMIS Rollover Study.
Authors
Neal D. Shore
Carolina Urologic Research Center/Genesis Care, Myrtle Beach, SC
Neal D. Shore , Murilo de Almeida Luz , Albertas Ulys , Jorge A. Ortiz , Shankar Srinivasan , Etah Kurland , Karim Fizazi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04464226
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 147)
DOI
10.1200/JCO.2023.41.6_suppl.147
Abstract #
147
Poster Bd #
E7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS.
First Author: Karim Fizazi
Poster
2020 ASCO Virtual Scientific Program
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Karim Fizazi
Poster
2020 ASCO Virtual Scientific Program
DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.
First Author: Evan Y. Yu
Poster
2023 ASCO Genitourinary Cancers Symposium
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
First Author: Simon J. Crabb